Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.47 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.44 |
| ▸ | BMP4 | P12644 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.40 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27030554 | 0.85 | ALK (0.45) | ALKKDM1AMAP3K7TAB1 | |
| SCHEMBL25423868 | 0.79 | KDR (0.49) | KDRFLT1FLT4TGFBR1ACVR1 | |
| SCHEMBL19110487 | 0.76 | ACVR1 (0.62) | KDRFLT1FLT4TGFBR1ACVR1 | |
| SCHEMBL25222640 | 0.75 | KDR (0.46) | KDRFLT1FLT4TGFBR1ACVR1 | |
| SCHEMBL3122986 | 0.75 | ALK (0.47) | ALKIRAK4KDM1AMAP3K7TAB1 | |
| SCHEMBL30440960 | 0.74 | ALK (0.46) | ALKTGFBR1IRAK4KDM1AMKNK1 | |
| SCHEMBL25291998 | 0.73 | PRKAB2 (0.38) | KDRFLT1FLT4PRKAB1IRAK4 | |
| SCHEMBL31590458 | 0.72 | RET (0.40) | ALK | |
| SCHEMBL31487791 | 0.71 | MAP4K3 (0.44) | ALKACVR1IRAK4BMPR1BBMPR1A | |
| SCHEMBL27030656 | 0.70 | ALK (0.48) | KDRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024233967-A2 | SIK INHIBITORS TO TREAT CHRONIC KIDNEY DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4192459-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | KDR 1018/4885FLT1 2688/4885FLT4 2671/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | KDR 2083/4885FLT1 3111/4885FLT4 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.